The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts

Cancer Cell

Volumn 1, Issue 4, 2002, Pages 393-401

  Lessnick, Stephen L ^a,b   Dacwag, Caroline S ^a   Golub, Todd R ^a,b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; ANTIINFECTIVE AGENT; EWS FLI FUSION PROTEIN; EWS-FLI FUSION PROTEIN; ONCOPROTEIN; PRIMER DNA; TETRACYCLINE DERIVATIVE; TRANSCRIPTION FACTOR;

ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER INHIBITION; CLINICAL FEATURE; CONTROLLED STUDY; EWING SARCOMA; FIBROBLAST CULTURE; GENE EXPRESSION PROFILING; GENE FUSION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; TRANSCRIPTION REGULATION; UPREGULATION; BONE TUMOR; CELL CULTURE; CELL DIVISION; CELL SURVIVAL; CELL TRANSFORMATION; CHEMISTRY; CYTOLOGY; DNA MICROARRAY; ENZYMOLOGY; FIBROBLAST; GENETIC TRANSFECTION; GENETICS; METABOLISM; MUTATION; NEWBORN; PHYSIOLOGY; RETROVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTI-BACTERIAL AGENTS; BONE NEOPLASMS; CELL DIVISION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; DNA PRIMERS; FIBROBLASTS; GENE EXPRESSION PROFILING; HUMANS; INFANT, NEWBORN; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENE PROTEINS, FUSION; RETROVIRIDAE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SARCOMA, EWING'S; TETRACYCLINES; TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036560740     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(02)00056-9     Document Type: Article

References (37)

1. Ambros, I.M., Ambros, P.F., Strehl, S., Kovar, H., Gadner, H., and Salzer-Kuntschik, M. (1991). MIC2 is a specific marker for Ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. Cancer 67, 1886-1893.
2. Arvand, A., Bastians, H., Welford, S.M., Thompson, A.D., Ruderman, J.V., and Denny, C.T. (1998). EWS/FLI1 up regulates mE2-C, a cyclin-selective ubiquitin conjugating enzyme involved in cyclin B destruction. Oncogene 17, 2039-2045.
3. Bates, S., Phillips, A.C., Clark, P.A., Stott, F., Peters, G., Ludwig, R.L., and Vousden, K.H. (1998). p14ARF links the tumour suppressors RB and p53. Nature 395, 124-125.
4. Damalas, A., Kahan, S., Shtutman, M., Ben-Ze'ev, A., and Oren, M. (2001). Deregulated beta-catenin induces a p53- and ARF-dependent growth arrest and cooperates with Ras in transformation. EMBO J. 20, 4912-4922.
5. Dellatre, O., Zucman, J., Plougastel, B., Desmaze, C., Melot, T., Peter, M., Heinrich, K., Houbert, I., de Jong, P., Rouleau, G., et al. (1992). Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359, 162-165.
6. Deneen, B., and Denny, C.T. (2001). Loss of p16 pathways stabilizes EWS/ FLI1 expression and complements EWS/FLI1 mediated transformation. Oncogene 20, 6731-6741.
7. de Stanchina, E., McCurrach, M.E., Zindy, F., Shieh, S., Ferbeyre, G., Samuelson, A.V., Prives, C., Roussel, M.F., Sherr, C.J., and Lowe, S.W. (1998). E1A signaling to p53 involves the p19ARF tumor suppressor. Genes Dev. 12, 2434-2442.
8. Fellinger, E.J., Garin-Chesa, P., Triche, T.J., Huvos, A.G., and Rettig, W.J. (1991). Immunohistochemical analysis of Ewing's sarcoma cell surface antigen p30/32MIC2. Am. J. Pathol. 139, 317-325.
9. Golub, T.R., Slonim, D.K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J.P., Coller, H., Loh, M.L., Downing, J.R., Caligiuri, M.A., et al. (1999). Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286, 531-537.
10. Hahn, W.C., Dessain, S.K., Brooks, M.W., King, J.E., Elenbaas, B., Sabatini, D.M., DeCaprio, J.A., and Weinberg, R.A. (2002). Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol. Cell. Biol. 22, 2111-2123.
11. Haupt, Y., Maya, R., Kazaz, A., and Oren, M. (1997). Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299.
12. Khan, J., Wei, J.S., Ringner, M., Saal, L.H., Ladanyi, M., Westermann, F., Berthold, F., Schwab, M., Antonescu, C.R., Peterson, C., and Meltzer, P.S. (2001). Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat. Med. 7, 673-679.
13. Kim, J., and Pelletier, J. (1999). Molecular genetics of chromosome translocations involving EWS and related family members. Physiol. Genomics 1, 127-138.
14. Kovar, H. (1998). Ewing's sarcoma and peripheral primitive neuroectodermal tumors after their genetic union. Curr. Opin. Oncol. 10, 334-342.
15. Kovar, H., Auinger, A., Jug, G., Aryee, D., Zoubek, A., Salzer-Kuntschik, M., and Gadner, H. (1993). Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours. Oncogene 8, 2683-2690.
16. Kovar, H., Jug, G., Aryee, D., Zoubek, A., Ambros, P., Gruber, B., Windhager, R., and Gadner, H. (1997). Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors. Oncogene 15, 2225-2232.
17. Kubbutat, M.H., Jones, S.N., and Vousden, K.H. (1997). Regulation of p53 stability by Mdm2. Nature 387, 299-303.
18. Ladanyi, M., Lewis, R., Jhanwar, S.C., Gerald, W., Huvos, A.G., and Healey, J.H. (1995). MDM2 and CDK4 gene amplification in Ewing's sarcoma. J. Pathol. 175, 211-217.
19. Lessnick, S.L., Braun, B.S., Denny, C.T., and May, W.A. (1995). Multiple domains mediate transformation by the Ewing's sarcoma EWS/FLI-1 fusion gene. Oncogene 10, 423-431.
20. May, W.A., Gishizky, M.L., Lessnick, S.L., Lunsford, L.B., Lewis, B.C., Delattre, O., Zucman, J., Thomas, G., and Denny, C.T. (1993a). Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc. Natl. Acad. Sci. USA 90, 5752-5756.
21. May, W.A., Lessnick, S.L., Braun, B.S., Klemsz, M., Lewis, B.C., Lunsford, L.B., Hromas, R., and Denny, C.T. (1993b). The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol. Cell. Biol. 13, 7393-7398.
22. McKeon, C., Thiele, C.J., Ross, R.A., Kwan, M., Triche, T.J., Miser, J.S., and Israel, M.A. (1988). Indistinguishable patterns of protooncogene expression in two distinct but closely related tumors: Ewing's sarcoma and neuroepithelioma. Cancer Res. 48, 4307-4311.
23. Morgenstern, J.P., and Land, H. (1990). Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18, 3587-3596.
24. Palmero, I., Pantoja, C., and Serrano, M. (1998). p19ARF links the tumour suppressor p53 to Ras. Nature 395, 125-126.
25. Patino-Garcia, A., and Sierrasesumaga, L. (1997). Analysis of the p16INK4 and TP53 tumor suppressor genes in bone sarcoma pediatric patients. Cancer Genet. Cytogenet. 98, 50-55.
26. Pomerantz, J., Schreiber-Agus, N., Liegeois, N.J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.W., et al. (1998). The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92, 713-723.
27. Prendergast, G.C. (1999). Mechanisms of apoptosis by c-Myc. Oncogene 18, 2967-2987.
28. Serrano, M., Lin, A.W., McCurrach, M.E., Beach, D., and Lowe, S.W. (1997). Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593-602.
29. Shaulian, E., Zauberman, A., Ginsberg, D., and Oren, M. (1992). Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. Mol. Cell. Biol. 12, 5581-5592.
30. Sorensen, P.H.B., and Triche, T.J. (1996). Gene fusions encoding chimaeric transcription factors in solid tumors. Semin. Cancer Biol. 7, 3-14.
31. Stott, F.J., Bates, S., James, M.C., McConnell, B.B., Starborg, M., Brookes, S., Palmero, I., Ryan, K., Hara, E., Vousden, K.H., and Peters, G. (1998). The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17, 5001-5014.
32. Tamayo, P., Slonim, D., Mesirov, J., Zhu, Q., Kitareewan, S., Dmitrovsky, E., Lander, E.S., and Golub, T.R. (1999). Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. Proc. Natl. Acad. Sci. USA 96, 2907-2912.
33. Teitell, M.A., Thompson, A.D., Sorensen, P.H., Shimada, H., Triche, T.J., and Denny, C.T. (1999). EWS/ETS fusion genes induce epithelial and neuroectodermal differentiation in NIH 3T3 fibroblasts. Lab. Invest. 79, 1535-1543.
34. Vousden, K. (1993). Interactions of human papillomavirus transforming proteins with the products of tumor suppressor genes. FASEB J. 7, 872-879.
35. Wei, W., Hemmer, R.M., and Sedivy, J.M. (2001). Role of p14(ARF) in replicative and induced senescence of human fibroblasts. Mol. Cell. Biol. 21, 6748-6757.
36. Zhang, Y., Xiong, Y., and Yarbrough, W.G. (1998). ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92, 725-734.
37. Zindy, F., Eischen, C.M., Randle, D.H., Kamijo, T., Cleveland, J.L., Sherr, C.J., and Roussel, M.F. (1998). Myc signalling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12, 2424-2433.